SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Profitability
This table compares SOPHiA GENETICS and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -110.71% | -55.06% | -38.33% |
| Caribou Biosciences | -1,290.81% | -45.46% | -38.07% |
Institutional and Insider Ownership
31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 4 | 0 | 2.80 |
| Caribou Biosciences | 0 | 0 | 5 | 0 | 3.00 |
SOPHiA GENETICS presently has a consensus price target of $7.40, indicating a potential upside of 101.09%. Caribou Biosciences has a consensus price target of $10.33, indicating a potential upside of 720.11%. Given Caribou Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than SOPHiA GENETICS.
Volatility and Risk
SOPHiA GENETICS has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500.
Earnings & Valuation
This table compares SOPHiA GENETICS and Caribou Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $62.37 million | 3.86 | -$78.98 million | ($1.09) | -3.38 |
| Caribou Biosciences | $34.48 million | 3.31 | -$102.07 million | ($1.65) | -0.76 |
SOPHiA GENETICS has higher revenue and earnings than Caribou Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
